Clinical Trials · NCT07579936
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Enrollment
- 200
- Start date
- Apr 2026
- Locations
- 1 site, China
- Primary endpoint
- The incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) between each intervention group and the control group during the treatment period，about 10weeks